Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 032: Nivolumab ± Ipilimumab in Advanced or Metastatic Solid Tumors
2024-516540-25-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic cancer (PC) and 3 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Objective response rate. Started Sep 2024; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
triple-negative breast cancer (TNBC)gastric cancer (GC)pancreatic cancer (PC)small cell lung cancer (SCLC)bladder cancer
Beyond the preview
Go deeper on 2024-516540-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516540-25-00.